Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Source: SeekingAlpha
2026-03-26 06:55:55 ET
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome March 25, 2026 12:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Denali Therapeutics Inc.
NASDAQ: DNLI
DNLI Trading
5.98% G/L:
$19.235 Last:
810,518 Volume:
$18.90 Open:
DNLI Latest News
March 25, 2026 11:50:28 am
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH(TM) (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
February 26, 2026 04:01:00 pm
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
DNLI Stock Data
$3,127,833,066
136,297,507
0.26%
87
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
